CC
NVO

Chase Coleman’s Novo Nordisk NVO Stock Holding History

Chase Coleman’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,269,000
Closed -$87.6M – 59
2025
Q2 		$87.6M Hold
1,269,000
– – 0.26% 38
2025
Q1 		$88.1M Hold
1,269,000
– – 0.33% 39
2024
Q4 		$109M Hold
1,269,000
– – 0.41% 36
2024
Q3 		$151M Hold
1,269,000
– – 0.64% 27
2024
Q2 		$181M Hold
1,269,000
– – 0.84% 25
2024
Q1 		$163M Hold
1,269,000
– – 0.89% 24
2023
Q4 		$131M Hold
1,269,000
– – 0.93% 25
2023
Q3 		$115M Hold
1,269,000
– – 0.85% 27
2023
Q2 		$103M Buy
+1,269,000
New +$104M 0.86% 24

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Chase Coleman's NVO Position: Q3 2025 in Review

Chase Coleman sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 1,269,000 shares — an estimated $87.6M sold.

Chase Coleman first reported a position in NVO in Q2 2023 and held it in 9 quarters. The position peaked at $181M in Q2 2024. 1,397 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Chase Coleman reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Chase Coleman sold 1,269,000 Novo Nordisk shares in Q3 2025, an estimated $87.6M.
  • Chase Coleman first reported a position in Novo Nordisk in Q2 2023 and held it in 9 quarters.
  • Chase Coleman's Novo Nordisk position peaked at $181M in Q2 2024.
  • 1,397 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Tiger Global Management's 13F filing for Q3 2025, filed 14 Nov 2025.